How do socio-demographic and clinical factors interact with adherence attitude profiles in schizophrenia? A cluster-analytical approach

Psychiatry Research

Volumn 187, Issue 1-2, 2011, Pages 55-61

  Beck, Eva Marina ^a   Cavelti, Marialuisa ^a   Wirtz, Markus ^b   Kossowsky, Joe ^c   Vauth, Roland ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF EDUCATION FREIBURG   (Germany)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Antipsychotics; Cluster analysis; Compliance; Insight; Psychosis; Shared decision making (SDM)

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; DEPRESSION; FEMALE; HOSPITAL READMISSION; HUMAN; HUMAN RELATION; MAJOR CLINICAL STUDY; MALE; MOTIVATION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SOCIAL ASPECT; SYMPTOMATOLOGY; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; ATTITUDE TO HEALTH; CLUSTER ANALYSIS; DEMOGRAPHY; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 79953125297     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2010.10.012     Document Type: Article

References (59)

1. Adewuya A.O., Ola B.A., Mosaku S.K., Fatoye F.O., Eegunranti A.B. Attitude towards antipsychotics among out-patients with schizophrenia in Nigeria. Acta Psychiatrica Scandinavica 2006, 113:207-211.
2. Altman D.G. Practical Statistics for Medical Research 1991, Chapman and Hall, London, England.
3. Beck A.T. The evolution of the cognitive model of depression and its neurobiological correlates. American Journal of Psychiatry 2008, 165:969-977.
4. Bischof G., Rumpf H.J., Hapke U., Meyer C., John U. Types of natural recovery from alcohol dependence: a cluster analytic approach. Addiction 2003, 98:1737-1746.
5. Chen A. Noncompliance in community psychiatry: a review of clinical interventions. Hospital & Community Psychiatry 1991, 42:282-287.
6. Clatworthy J., Buick D., Hankins M., Weinman J., Horne R. The use and reporting of cluster analysis in health psychology: a review. British Journal of Health Psychology 2005, 10:329-358.
7. Cuesta M.J., Peralta V. Psychopathological dimensions in schizophrenia. Schizophrenia Bulletin 1995, 21:473-482.
8. Day J.C., Bentall R.P., Roberts C., Randall F., Rogers A., Cattell D., Healy D., Rae P., Power C. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Archives of General Psychiatry 2005, 62:717-724.
9. Deegan P.E., Drake R.E. Shared decision making and medication management in the recovery process. Psychiatry Services 2006, 57:1636-1639.
10. Draine J., Solomon P. Explaining attitudes toward medication compliance among a seriously mentally ill population. Journal of Nervous and Mental Disease 1994, 182:50-54.
11. Fenton W.S., Blyler C.R., Heinssen R.K. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophrenia Bulletin 1997, 23:637-651.
12. First M.B., Gibbon M., Spitzer R.L., Williams J.B.W. User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders - Research Version 1996, Biometrics Research, New York.
13. Freudenreich O., Cather C., Evins A.E., Henderson D.C., Goff D.C. Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. Journal of Clinical Psychiatry 2004, 65:1372-1376.
14. Freudenreich O., Tranulis C. A prototype approach toward antipsychotic medication adherence in schizophrenia. Harvard Review of Psychiatry 2009, 17:35-40.
15. Gard D.E., Kring A.M., Gard M.G., Horan W.P., Green M.F. Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophrenia Research 2007, 93:253-260.
16. Giuffrida A., Torgerson D.J. Should we pay the patient? Review of financial incentives to enhance patient compliance. BMJ 1997, 315:703-707.
17. Hamann J., Mendel R.T., Fink B., Pfeiffer H., Cohen R., Kissling W. Patients' and psychiatrists' perceptions of clinical decisions during schizophrenia treatment. Journal of Nervous and Mental Disease 2008, 196:329-332.
18. Hautzinger, M., Bailer, M., 1993. ADS. Allgemeine Depressions Skala (Testmappe mit Handanweisung, je 20 Frageboegen L und K sowie Auswertungsschablone). Beltz, Weinheim.
19. Heinrichs R.W., Goldberg J.O., Miles A.A., McDermid V.S. Predictors of medication competence in schizophrenia patients. Psychiatry Research 2008, 157:47-52.
20. Hogan T.P., Awad A.G., Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychological Medicine 1983, 13:177-183.
21. Hwang S.S., Chang J.S., Lee K.Y., Ahn Y.M., Kim Y.S. The causal model of insight in schizophrenia based on the positive and negative syndrome scale factors and the structural equation modeling. Journal of Nervous and Mental Disease 2009, 197:79-84.
22. Jahn T., Pitschel-Walz G., Gsottschneider A., Frobose T., Kraemer S., Bauml J. Neurocognitive prediction of illness knowledge after psychoeducation in schizophrenia: results from the Munich COGPIP study. Psychological Medicine 2010, 19:1-12.
23. Janssen B., Gaebel W., Haerter M., Komaharadi F., Lindel B., Weinmann S. Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders. Psychopharmacology (Berl) 2006, 187:229-236.
24. Johnsen E., Jorgensen H.A. Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry 2008, 8:31.
25. Kane J.M. Treatment adherence and long-term outcomes. CNS Spectrums 2007, 12:21-26.
26. Karow A., Czekalla J., Dittmann R.W., Schacht A., Wagner T., Lambert M., Schimmelmann B.G., Naber D. Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. Journal of Clinical Psychiatry 2007, 68:75-80.
27. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13:261-276.
28. Kim S.W., Shin I.S., Kim J.M., Yang S.J., Shin H.Y., Yoon J.S. Association between attitude toward medication and neurocognitive function in schizophrenia. Clinical Neuropharmacology 2006, 29:197-205.
29. Kozuki Y., Schepp K.G. Adherence and nonadherence to antipsychotic medications. Issues in Mental Health Nursing 2005, 26:379-396.
30. Lacro J.P., Dunn L.B., Dolder C.R., Leckband S.G., Jeste D.V. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. Journal of Clinical Psychiatry 2002, 63:892-909.
31. Lincoln T.M., Lullmann E., Rief W. Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review. Schizophrenia Bulletin 2007, 33:1324-1342.
32. Loffler W., Kilian R., Toumi M., Angermeyer M.C. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment. Pharmacopsychiatry 2003, 36:105-112.
33. Lysaker P.H., Davis L.W., Tsai J. Suspiciousness and low self-esteem as predictors of misattributions of anger in schizophrenia spectrum disorders. Psychiatry Research 2009, 166:125-131.
34. Macharia W.M., Leon G., Rowe B.H., Stephenson B.J., Haynes R.B. An overview of interventions to improve compliance with appointment keeping for medical services. JAMA 1992, 267:1813-1817.
35. McEvoy J.P., Freter S., Everett G., Geller J.L., Appelbaum P., Apperson L.J., Roth L. Insight and the clinical outcome of schizophrenic patients. Journal of Nervous and Mental Disease 1989, 177:48-51.
36. Miller G.A., Chapman J.P. Misunderstanding analysis of covariance. Journal of Abnormal Psychology 2001, 110:40-48.
37. Mitchell A.J. Adherence behaviour with psychotropic medication is a form of self-medication. Medical Hypotheses 2007, 68:12-21.
38. Mohamed S., Rosenheck R., McEvoy J., Swartz M., Stroup S., Lieberman J.A. Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophrenia Bulletin 2009, 35:336-346.
39. Mueser K.T., Corrigan P.W., Hilton D.W., Tanzman B., Schaub A., Gingerich S., Essock S.M., Tarrier N., Morey B., Vogel-Scibilia S., Herz M.I. Illness management and recovery: a review of the research. Psychiatric Services 2002, 53:1272-1284.
40. Nakagami E., Xie B., Hoe M., Brekke J.S. Intrinsic motivation, neurocognition and psychosocial functioning in schizophrenia: testing mediator and moderator effects. Schizophrenia Research 2008, 105:95-104.
41. Nose M., Barbui C., Tansella M. How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychological Medicine 2003, 33:1149-1160.
42. Pijnenborg G.H., Withaar F.K., Brouwer W.H., Timmerman M.E., van den Bosch R.J., Evans J.J. The efficacy of SMS text messages to compensate for the effects of cognitive impairments in schizophrenia. British Journal of Clinical Psychology 2010, 49:259-274.
43. Radloff L.S. The CES-D scale: a self-report depression scale for research in the general population. Applied Psychological Measurement 1977, 1:385-401.
44. Rettenbacher M.A., Hofer A., Eder U., Hummer M., Kemmler G., Weiss E.M., Fleischhacker W.W. Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication. Journal of Clinical Psychiatry 2004, 65:1211-1218.
45. Rocca P., Crivelli B., Marino F., Mongini T., Portaleone F., Bogetto F. Correlations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophrenia. Comprehensive Psychiatry 2008, 49:170-176.
46. Rummel-Kluge C., Schuster T., Peters S., Kissling W. Partial compliance with antipsychotic medication is common in patients with schizophrenia. Australian and New Zealand Journal of Psychiatry 2008, 42:382-388.
47. Rusch N., Todd A.R., Bodenhausen G.V., Weiden P.J., Corrigan P.W. Implicit versus explicit attitudes toward psychiatric medication: implications for insight and treatment adherence. Schizophrenia Research 2009, 112:119-122.
48. Santone G., Rucci P., Muratori M.L., Monaci A., Ciarafoni C., Borsetti G. Attitudes toward medication in inpatients with schizophrenia: a cluster analytic approach. Psychiatry Research 2008, 158:324-334.
49. Sapra M., Vahia I.V., Reyes P.N., Ramirez P., Cohen C.I. Subjective reasons for adherence to psychotropic medication and associated factors among older adults with schizophrenia. Schizophrenia Research 2008, 106:348-355.
50. Shrout P.E., Fleiss J.L. Intraclass correlations: uses in assessing rater reliability. Psychological Bulletin 1979, 86:420-428.
51. Suarez D., Haro J.M. Overview of the findings from the European SOHO study. Expert Review of Neurotherapeutics 2008, 8:873-880.
52. Taylor D.M., Fischetti C., Sparshatt A., Thomas A., Bishara D., Cornelius V. Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice. Journal of Clinical Psychiatry 2009, 70:196-200.
53. Van Putten T., May P.R. Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point. Archives of General Psychiatry 1978, 35:477-480.
54. Van Randenborgh A., De Jong-Meyer R., Huffmeier J. Decision making in depression: differences in decisional conflict between healthy and depressed individuals. Clinical Psychology & Psychotherapy 2010, 17:285-298.
55. Vauth R., Loschmann C., Rusch N., Corrigan P.W. Understanding adherence to neuroleptic treatment in schizophrenia. Psychiatry Research 2004, 126:43-49.
56. Velligan D.I., Lam Y.W., Glahn D.C., Barrett J.A., Maples N.J., Ereshefsky L., Miller A.L. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophrenia Bulletin 2006, 32:724-742.
57. Weiden P., Rapkin B., Mott T., Zygmunt A., Goldman D., Horvitz-Lennon M., Frances A. Rating of Medication Influences (ROMI) scale in schizophrenia. Schizophrenia Bulletin 1994, 20:297-307.
58. Weiden P.J., Schooler N.R., Weedon J.C., Elmouchtari A., Sunakawa A., Goldfinger S.M. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. Journal of Clinical Psychiatry 2009, 70:1397-1406.
59. Yamada K., Watanabe K., Nemoto N., Fujita H., Chikaraishi C., Yamauchi K., Yagi G., Asai M., Kanba S. Prediction of medication noncompliance in outpatients with schizophrenia: 2-year follow-up study. Psychiatry Research 2006, 141:61-69.